amyloid-beta fibril formation inhibitor (Novartis)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Nameamyloid-beta fibril formation inhibitor (Novartis)
Drug Alias NameNCP-AAM155NVP-AAM155NCP-AAM147NVP-AAM147
ClassificationSmall molecules
Mechanisms of ActionBeta amyloid A4 protein aggregation inhibitorsNeuroprotectants
TargetsBeta amyloid A4 protein
Therapy Area/IndicationsAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNovartis Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Ag
Active IndicationsN/A
Inactive IndicationsAlzheimer Disease

Other Information

ATC CodeN/A
Related LinksN/A